- Previous Close
0.4150 - Open
0.4200 - Bid 0.4350 x --
- Ask 0.4400 x --
- Day's Range
0.4200 - 0.4400 - 52 Week Range
0.1900 - 0.5350 - Volume
3,229,893 - Avg. Volume
7,716,593 - Market Cap (intraday)
795.885M - Beta (5Y Monthly) 1.83
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0200 - Earnings Date Feb 26, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
0.65
Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia and the United States. Its product pipeline includes Sofpironium Bromide, a drug in development for the treatment of primary axillary hyperhidrosis that has completed Phase 3 clinical programs; BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIa clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 that is in Phase II clinical trials for the treatment of papulopustular rosacea; and BTX 1204A for the treatment of atopic dermatitis. Botanix Pharmaceuticals Limited was incorporated in 1984 and is based in West Perth, Australia.
www.botanixpharma.comRecent News: BOT.AX
View MorePerformance Overview: BOT.AX
Trailing total returns as of 3/20/2025, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BOT.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BOT.AX
View MoreValuation Measures
Market Cap
759.29M
Enterprise Value
711.72M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.23k
Price/Book (mrq)
8.21
Enterprise Value/Revenue
1.25k
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-34.35%
Return on Equity (ttm)
-56.99%
Revenue (ttm)
2.07M
Net Income Avi to Common (ttm)
-39.29M
Diluted EPS (ttm)
-0.0200
Balance Sheet and Cash Flow
Total Cash (mrq)
48.44M
Total Debt/Equity (mrq)
0.94%
Levered Free Cash Flow (ttm)
-26.79M